Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.39 |
| ▸ | CTSD | P07339 | 7/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 3/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446461 | 0.80 | MAOB (0.40) | ITGALITGB2ICAM1TDP2 | |
| SCHEMBL430515 | 0.75 | BACE1 (0.71) | BACE1CTSD | |
| SCHEMBL446435 | 0.75 | BACE1 (0.71) | BACE1CTSD | |
| SCHEMBL464641 | 0.75 | BACE1 (0.71) | BACE1CTSD | |
| SCHEMBL447638 | 0.74 | BACE1 (0.46) | BACE1CTSDITGALITGB2ICAM1 | |
| SCHEMBL448438 | 0.67 | ESR1 (0.37) | TDP2 | |
| SCHEMBL447377 | 0.66 | BACE1 (0.71) | BACE1CTSD | |
| SCHEMBL464669 | 0.66 | BACE1 (0.71) | BACE1CTSD | |
| SCHEMBL429993 | 0.66 | BACE1 (0.71) | BACE1CTSD | |
| SCHEMBL446230 | 0.65 | BACE1 (0.73) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885CTSD 427/4885PGR 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.